CCC
GSK icon

Crescent Capital Consulting’s GSK GSK Stock Holding History

Crescent Capital Consulting’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$98K Buy
1,773
+17
+1% +$884 0.02% 231
2021
Q3 		$83K Sell
1,756
-90
-5% -$4.52K 0.02% 245
2021
Q2 		$91K Sell
1,846
-85
-4% -$4.08K 0.02% 228
2021
Q1 		$85K Buy
1,931
+320
+20% +$14.5K 0.02% 242
2020
Q4 		$74K Buy
+1,611
New +$74K 0.02% 218

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Crescent Capital Consulting's GSK Position: Q4 2021 in Review

Crescent Capital Consulting increased its GSK (GSK) stake by 0.97% in Q4 2021, buying an estimated $884 and bringing the position to 1,773 shares worth $98K. The position accounts for 0.02% of the portfolio, ranked #231.

Crescent Capital Consulting first reported a position in GSK in Q4 2020 and has held it in 5 quarters since. 919 funds tracked by Wall St. Rank hold GSK as of Q4 2021.

  • Crescent Capital Consulting held 1,773 shares of GSK worth $98K as of Q4 2021.
  • Crescent Capital Consulting bought 17 GSK shares in Q4 2021, an estimated $884.
  • GSK made up 0.02% of Crescent Capital Consulting's portfolio in Q4 2021, its #231 holding.
  • Crescent Capital Consulting first reported a position in GSK in Q4 2020 and has held it in 5 quarters since.
  • 919 funds tracked by Wall St. Rank held GSK as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.